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MicroRNAs (miRNAs) represent a class of small non-coding RNAs that regulate gene expression at
the post-transcriptional levels. Recent studies show that miRNAs may function as oncogenes or
tumor suppressor genes. In this study, we demonstrated that miR-518b was down-regulated in
esophageal squamous cell carcinoma (ESCC) tissues and correlated with metastasis and survival.
miR-518b suppressed the proliferation by inducing apoptosis and repressed the invasion in ESCC
cells, but had no effect on the cell cycle. Furthermore, Rap1b was revealed to be directly regulated
by miR-518b. These ﬁndings indicate that miR-518b may function as a tumor suppressor by target-
ing Rap1b in the development of ESCC and has important clinical and prognostic value.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Esophageal cancer is the sixth leading cause of cancer deaths, of
which esophageal squamous cell carcinoma (ESCC) accounts for
most cases. The incidence of ESCC appears to be broadly varied
by geographic locations. The highest incidence rates were found
in China, Iran, South America, and South Africa, and one-half of
all ESCC cases in the world occur in China [1]. Despite a myriad
of improvements in both diagnostic and therapeutic techniques
over the past three decades, esophageal cancer continues to have
a poor prognosis, with 5-year survival rates between 10% and
13% [2]. Research over the last 30 years has identiﬁed a number
of genetic alterations relating to induction of ESCC. However, the
molecular mechanisms responsible for the cellular deregulation
in ESCC have not been fully understood [3].
MicroRNAs (miRNAs) represent a class of small non-coding
RNAs that regulate gene expression at the post-transcriptional
levels. MiRNAs play important roles in a series of biologicalchemical Societies. Published by E
Thoracic Oncosurgery, First
iversity, Yanta West Road No.
029 85323112.
jshxjtu@gmail.com (J. Wang).processes and changes in miRNAs expression have been observed
in a variety of human pathological conditions. Recent studies
showed that miRNAs were aberrantly regulated in different onco-
genic pathways and/or various types of cancers, indicating that
some miRNAs may function as oncogenes or tumor suppressor
genes [4]. For example, miR-21 is over-expressed in most tumor
types, and acts as an oncogene by targeting many tumor suppres-
sor genes related to proliferation, apoptosis, and invasion [5]. And
the human let-7 family of miRNAs, containing 13 members located
on nine different chromosomes, was deregulated in many human
cancers and restoration of expression may be a useful therapeutic
option in cancers [6]. These ﬁndings also point out the potential va-
lue of miRNA in cancer screening, diagnosis, treatment, and prog-
nosis. Currently, only limited data is available on the miRNA
signature of ESCC. In our previous study, we investigated the miR-
NAs expression proﬁle of ESCC. The results show the deregulated
expression of miRNAs in ESCC, and 11 miRNAs of which were con-
sidered signiﬁcant statistical difference [7]. It is of great impor-
tance to further explore the clinical signiﬁcance, biological
functions, and target genes of miRNAs in ESCC.
In this study, we examined the expression level of miR-126,
miR-518b, and miR-433 in human ESCC specimens, and explored
their relationship with clinicopathologic features and prognosis.lsevier B.V. All rights reserved.
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tial target genes in ESCC cells. Our data suggest that miR-518b
may exert its tumor suppressor function via targeting Rap1b.Fig. 1. The expression of miR-518b in esophageal squamous cell carcinoma and its
association with survival. (A) The fold change in miR-126, miR-518b, and miR-433
expression in ESCC versus normal tissues. (B) Progression free survival curves for
ESCC patients plotted on miR-518b expression.2. Materials and methods
2.1. Patient samples and cell lines
Fresh cancer tissues and paired normal adjacent tissues (NAT)
were obtained from patients with ESCC in First Afﬁliated Hospital
of Medical School of Xi’an Jiaotong University from Oct-2008 to
Oct-2010. The tissue samples were collected from patients under-
going surgery without chemo- and radiotherapy. Tissues were
snap frozen in liquid nitrogen and stored at 80 C until RNA
extraction. Tissue sections were stained with H&E for histological
diagnosis and heterogeneity evaluation. Only those sections com-
prised of more than 70% tumor cells in total cell population were
used in this study. All the samples were accrued with informed
consent and the Institutional Ethics Committee approval for this
project was obtained. The median follow-up time for disease pro-
gress was 14.05 months, ranging from 1 to 22 months.
The ESCC cell lines (Eca109, Ec9706, and TE-1) were from the
Cell Bank of Shanghai (China) and cultured in RPMI 1640 medium
supplemented with 10% FBS, 100 units/ml penicillin and 100 g/ml
streptomycin at 37 C in a 5% CO2 incubator.
2.2. RNA extraction and quantitative reverse transcription-PCR (qRT-
PCR)
Total RNA was isolated with Trizol reagent (Invitrogen, Carls-
bad, CA, USA) and RNeasy mini kit (QIAGEN, Valencia, CA, USA) fol-
lowing the manufacturer’s instruction. qRT-PCR was carried out
using a BioRad iQ5 Real-Time PCR Detection System to conﬁrm
the expression levels of mRNAs and miRNAs as described before
[7]. U6 snRNA and GAPDH mRNA levels were used for normaliza-
tion. The expression levels in cancer tissues relative to NAT
were calculated using the formula: 2DDCT, DDCT = (CTmiRNA
CTU6 RNA)ESCC  (CTmiRNA  CTU6 RNA)NAT.
2.3. Plasmid construction
Anti-miR-518b inhibitor (anti-miR-518b) and anti-miR-
Inhibitors-Negative Control (Control) were purchased from
AngRang Inc. (Xi’an, China). The sequence of precursor miR-518b
was synthesized and cloned into pcDNA™6.2-GW/EmGFP-miR
expression vector (Invitrogen, Carlsbad, CA, USA). The Rap1b
30-UTR target site sequence and sequence with mutation of three
bases in the miR-518b target-site were synthesized and cloned
into downstream of the luciferase gene in the pmirGLO luciferase
vector (Promega, Madison, WI, USA). These vectors were named
pcDNA-miR-518b, Rap1b-30-UTR-WT and Rap1b-30-UTR-MU,
respectively. All constructs were sequenced.
2.4. Cell transfection
Cell transfection was performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
protocol. Total RNA and protein were prepared 48 h after transfec-
tion and were used for qRT-PCR or Western blot analysis.
2.5. MTT assays
The cells were seeded at a density of 5  103 cells/well in 96-
well plates at a ﬁnal volume of 180 ll in incubation, at 37 C, with
5% CO2. After different time incubation, 20 ll of 5 mg/ml solution ofMTT (Sigma, St. Louis, MO, USA) in PBS was added to each well. The
plates were then incubated for 4 h at 37 C. The reaction was then
solubilized in 100% dimethylsulfoxide (Sigma, St. Louis, MO, USA),
20 ll/well, and shaken for 15 min. Absorbance of each well was
measured on a multidetection microplate reader (BMG LABTECH,
Durham, NC, USA) at a wavelength of 570 nm. pcDNA™6.2-GW/
EmGFP-miR (mock) and anti-miR-Inhibitors-Negative Control
(Control) were used as the control for pcDNA-miR-518b and anti-
miR-518b inhibitor, respectively. All experiments were done in
quadruplicate.
2.6. Cell cycle analysis
After harvested by trypsinization and washed with PBS, cells
were ﬁxed in ice-cold 70% ethanol, washed, and resuspended in
1 ml PBS containing ﬁnal concentrations of 1 mg/ml RNase A for
30 min at room temperature, and ﬁnally, stained with 20 lg/ml
propidium iodide (PI) for 30 min. The stained cells were analyzed
by ﬂow cytometry (FACSCalibur, BD Biosciences, San Jose, CA)
and DNA content was quantiﬁed using Coulter System software
(Beckman Coulter Inc., Fullerton, CA). All of the samples were as-
sayed in triplicate.
Table 1
Clinicopathologic variables and the expression status of miR-126, miR-518b, and miR-433.
Variables N miR-126 P miR-518b P miR-433 P
Low High Low High Low High
Age 0.232 1.000 0.722
<60 12 4 8 6 6 7 5
P60 18 10 8 9 9 9 9
Gende0072 1.000 0.109 0.694
Male 21 10 11 13 8 12 9
Female 9 4 5 2 7 4 5
Smoking 0.315 0.100 1.000
Yes 26 11 15 11 15 14 12
No 4 3 1 4 0 2 2
Drinking 0.072 1.000 0.657
Yes 24 9 15 12 12 12 12
No 6 5 1 3 3 4 2
Differentiation 0.329 0.388 0.690
Well 5 1 4 3 2 2 3
Moderate 16 7 9 6 10 8 8
Poor 9 6 3 6 3 6 3
TNM stage 0.732 0.715 0.299
I–II 16 7 9 9 7 7 9
III–IV 14 7 7 6 8 9 5
Lymph node 0.464 0.003 0.066
Metastasis 15 6 9 12 3 11 4
No metastasis 15 8 7 3 12 5 10
Table 2
Univariate analysis for progression free survival.
Variables N Progression free survival (months) P
Median ± SE 95% CI
miR-126 0.125
Low 14 16.24 ± 1.85 12.62–19.87
High 16 12.24 ± 1.63 9.03–15.42
miR-518b 0.002
Low 15 10.05 ± 1.66 6.80–13.30
High 15 17.82 ± 1.31 15.26–20.39
miR-433 0.263
Low 16 12.41 ± 1.83 8.81–16.00
High 14 15.92 ± 1.63 12.72–19.13
Age 0.389
<60 12 14.95 ± 1.99 11.04–18.86
P60 18 13.37 ± 1.68 10.08–16.67
Gender 0.122
Male 21 12.67 ± 1.48 9.77–15.57
Female 9 16.78 ± 2.09 12.68–20.88
Smoking 0.241
Yes 26 13.21 ± 1.38 10.51–15.91
No 4 18.5 ± 0.83 16.88–20.13
Drinking 0.139
Yes 24 13.20 ± 1.37 10.51–15.88
No 6 17.28 ± 3.08 11.23–23.32
Differentiation 0.688
Well 5 14.80 ± 3.91 7.13–22.47
Moderate 16 14.47 ± 1.59 11.35–17.59
Poor 9 11.98 ± 1.97 8.13–15.84
TNM stage 0.760
I–II 16 14.82 ± 1.67 11.54–18.10
III–IV 14 13.31 ± 2.01 9.37–17.25
Lymph node 0.018
Metastasis 15 10.97 ± 1.78 7.50–14.45
No metastasis 15 17.33 ± 1.42 14.56–20.11
Table 3
Multivariate Cox proportional hazards analysis for progression free survival.
Variables Progression free survival P
HR 95% CI
miR-126
High vs Low 2.144 0.68–6.78 0.194
miR-518b
Low vs High 6.88 1.03–45.84 0.046
miR-433
Low vs High 1.96 0.48–7.99 0.349
Lymph node
Metastasis vs No metastasis 1.66 0.183–15.06 0.652
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The cells were washed twice with cold 10 mM PBS and resus-
pended in 1 binding buffer (BD Biosciences, San Jose, CA, USA).Apoptosis in ESCC cells was quantiﬁed by staining with annexin
V-Phycoerythrin (PE) and 7-amino-actinomycin D (7-AAD). The
samples were analyzed using ﬂow cytometry (FACSCalibur, BD Bio-
sciences, San Jose, CA).
2.8. Cell invasion assay
For invasion assay, the membrane invasion culture system
(transwell membranes of 6.5 mm diameter and 8 lm pore size;
Costar) was used according to the standard protocol. Brieﬂy, Har-
vested cells (1  105) suspending in 100 ll of serum free RPMI
1640 were added into the upper compartment of the chamber. A
total of 1000 ll conditioned RPMI 1640 medium with 20% (v/v) fe-
tal bovine serum was used as a source of chemoattractant and
placed in bottom compartment of chamber. After 48 h, the non-
invasive cells on the upper surface of the membrane were removed
with a cotton swab. The transformed cells that migrated through
the Matrigel matrix and stuck to the lower surface of the mem-
brane were ﬁxed with 4% paraformaldehyde, stained with 1% crys-
tal purple. The invasive cells were then counted (ﬁve high-power
ﬁelds/chamber) using an inverted microscope. Each tests repeated
in triplicate.
Fig. 2. Effect of miR-518b on cell proliferation, cell cycle and apoptosis. (A) Anti-miR-518b inhibitor (anti-miR-518b)/pcDNA™6.2-GW/EmGFP-miR-518b (miR-518b) could
signiﬁcantly change the expression of miR-518b at 48 h after transfection compared with anti-miR-Inhibitors-Negative Control (Control)/pcDNA™6.2-GW/EmGFP-miR
(Mock). (B) After miR-518b or anti-miR-518b transduction, the cell growth of ESCC cells was analyzed at each different time point (24, 48, and 72 h, respectively) compared
with the controls by the MTT assay. (C) Flow cytometric analysis of the effect of miR-518b on the cell cycle of Eca109 cells. (D) Effect of alteration of miR-518b expression on
cell cycle detected by ﬂow cytometric analysis in total three ESCC cells. (E) Flow cytometric analysis of the effect of miR-518b on apoptosis of Eca109 cells. (F) Effect of
alteration of miR-518b expression on cell apoptosis detected by ﬂow cytometric analysis in total three ESCC cells. ⁄P < 0.05 compared with respective control.
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Anti-Rap1b and anti-b-actin antibodies were obtained from
Santa Cruz Biotech. For Western blot analyses, 20 lg of totalprotein were electrophoresed on a 10% SDS–PAGE gel, transferred
onto to PVDF membrane, blocked, and then incubated with pri-
mary antibody as indicated above. Corresponding horseradish per-
oxidase (HRP)-conjugated secondary antibody was then used on
Fig. 2 (continued)
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tion with enhanced ECL detection reagents (Amersham, Little Chal-
font, Buckinghamshire, England) according to the manufacturer’s
instructions, the membranes were visualized by exposure to X-
ray ﬁlm in dark. Densitometric analysis was performed using Scion
Image software.
2.10. Luciferase assay
Forty-eight hours after transfection, cells were assayed for both
ﬁreﬂy and renilla luciferase activity using the Dual-GLO Luciferase
Assay System (Promega, Madison,WI, USA). Brieﬂy, cells were lysed
and the ﬁreﬂy luciferase substrate was added (75 ll/well Dual-
GLO Substrate/Buffer). After 15 min, luciferase activity wasmeasured using a luminometer (BMG LABTECH, Durham, NC,
USA). Next the renilla luciferase substrate was added (75 ll/well
Stop & GLO Substrate/Buffer) and the luminescence measured
after further 10 min incubation. The renilla/ﬁreﬂy luciferase ratio
was calculated from the mean luminescence values of triplicate
wells, after blanking against values from untransfected cells. The
percentage knockdown using test miR-518b was calculated com-
pared with the control and data are shown as the mean of three
experimental replicates.
2.11. Immunohistochemical staining and analysis
The Streptavidin-Peroxidase technique (Golden Bridge
International: SP-9000) was used according the manufacturer’s
Fig. 2 (continued)
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Biotechnology, Santa Cruz, CA: sc-1481) was used at dilutions of
1:400. An irrelevant sheep antiserum served as a negative control.
Two observers who were blinded to clinical features evaluated
staining results independently and co-observed for a consensus
when they were divergent with the method as described [8].
2.12. Statistical analysis
To investigate the association with clinicopathologic features
and survival, miRNA expression values were dichotomized into
low and high groups using the median expression value within
cohort as a cutoff. A Fisher’s exact text was used to analyze the rela-
tionship betweenmiRNAs expression level and various clinicopath-
ologic characteristics. The survival curves were built by the Kaplan–
Meier method, and the resulting curves were compared using the
log-rank test. The joint effect of covariables was examined using
the Cox proportional hazard regression model. For other analysis,
data are expressed as the mean ± standard deviation from at least
3 separate experiments performed in triplicate. Differencesbetween groups were assessed by unpaired, two-tailed Student’s t
test, P < 0.05 was considered signiﬁcant.
3. Results
3.1. miR-518b is down-regulated in ESCC and associated with shorter
progression free survival
We examined the expression of miR-126, miR-518b, and miR-
433 in a set of 30 paired samples using qRT-PCR. The results
showed that the three miRNAs are signiﬁcantly altered in ESCC tis-
sues when compared to the normal controls (P < 0.05, Fig. 1A).
miR-126 was up-expressed while miR-518b and miR-433 was
down-expressed in ESCC. Next, the correlation of miRNAs expres-
sion with the clinicopathologic factors was examined. There was
a correlation between expression status of miR-518b and metasta-
sis of lymph node (Table 1). Low expression of miR-518b and
metastasis of lymph nodes were relevant to decreased progress
free survival (PFS) through Kaplan–Meier survival curve analysis
with a log rank comparison, whereas other parameters were not
Fig. 2 (continued)
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were independent prognostic factors for PFS (Table 3).
3.2. miR-518b represses cell proliferation by inducing apoptosis in
ESCC cells
Since miR-518b had important relationship with clinicopatho-
logic factors and survival, we further investigated the function ofmiR-518b in ESCC. To determine the role of miR-518b in tumor cell
proliferation, the plasmid pcDNA™6.2-GW/EmGFP-miR-518b
(miR-518b) and an anti-miR-518b inhibitor (anti-miR-518b) were
used to over-express and block miR-518b expression in ESCC cells,
respectively. The results showed that the expression of miR-518b
was signiﬁcantly affected by the plasmids at 48 h after
transfection, so total RNA and protein were prepared 48 h after
transfection and were used for qRT-PCR or Western blot analysis
Fig. 2 (continued)
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pressed the cell viability, while down-expression of miR-518b pro-
moted the proliferation (Fig. 2B). Next, effect of miR-518b on cell
cycle and apoptosis was analyzed by ﬂow cytometry. The alteration
of miR-518b expression was ineffective in cell cycle distribution in
ESCC cells (Fig. 2C and D). ESCC cells transfected with miR-518b
showed enhanced apoptosis rate, including the early apoptosis
and late apoptosis, compared to mock group, while anti-
miR-518b group got the opposite results (Fig. 2E and F). These
results indicated that miR-518b suppressed the ability of ESCC
cells to proliferate by inducing apoptosis in ESCC cells.
3.3. miR-518b regulates cell invasion in vitro
We further analyzed the effects of miR-518b on the invasive
behavior of ESCC cell lines. After incubation, the cells migrated to
the basal side of the membrane were counted and captured
(Fig. 3A). The numbers of miR-518b-transfected ESCC cells passing
through the matrigel were signiﬁcantly lower than the numbers of
cells transfected with pcDNA™6.2-GW/EmGFP-miR (Mock). On the
contrary, the numbers of anti-miR-518b-transfected ESCC cells
passing through the matrigel were signiﬁcantly higher than the
numbers of cells transfected with anti-miR-Inhibitors-Negative
Control (Fig. 3B). These ﬁndings suggest that miR-518b expression
seems to be closely associated with the invasion of ESCC cell lines.
3.4. Rap1b is a target of miR-518b
Based on the correlation of miR-518b with metastasis of lymph
node and miR-518b-induced suppression of the invasion of ESCC
cell lines, we hypothesized thatmiR-518b inhibited themalignancyof ESCC cells by regulating oncogenes and/or genes involved in cell
invasion. We used the TargetScan (http://www.targetscan.org/l)
and MicroCosm (http://www.ebi.ac.uk/enright-srv/microcosm/
htdocs/targets/v5/) for prediction of targets of miR-518b. It was
showed that Rap1b, EGR1 (early growth response 1), TFAP2A
(transcription factor AP-2 alpha), HOXC8 (homeobox C8) and TSN
(translin) were some of the predicted targets of miR-518b. Since
Rap1b is known to play a role in the progression of angiogenesis
and migration, so we elected to validate the role of miR-518b on
the regulation of Rap1b [9].
First, we detected the expression of miR-518b and Rap1b in
ESCC cells by qRT-PCR or Western blots, respectively, using the
normal esophageal tissues as control. It was found that ESCC cells
had a lower level of miR-518b expression (Fig. 4A), a similar level
of Rap1b mRNA expression (Fig. 4B), and a higher level of Rap1b
protein expression (Fig. 4C). We then evaluated expression levels
of Rap1b in tissues by immunohistochemical analysis. It was dem-
onstrated that Rap1b up-regulated in tumor tissues compared with
NAT (Fig. 4D).
Further, we used Western blots to determine the effect of miR-
518b on levels of endogenous Rap1b protein in ESCC cells. We
showed that Rap1b protein expression was signiﬁcantly down-
regulated in extracts from miR-518b-transfected ESCC cells when
compared with miR-518b control-transfected ESCC cells (Fig. 4E).
But qRT-PCR analysis showed that miR-518b had no effect on the
mRNA expression of Rap1b (Fig. 4F).
Last, we constructed luciferase reporter vectors to determine
whether miR-518b was capable of targeting Rap1b (Fig. 4G). After
co-transfection of miR-518b with Rap1b-wild type or mutated 30-
UTR luciferase reporter vector into ESCC cells, we found that
miR-518b reduced Rap1b 30-UTR luciferase activity compared with
Fig. 2 (continued)
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the mutated Rap1b 30-UTR luciferase reporter (Fig. 4H, I, and J),
indicating that miR-518b indeed was able to silence Rap1b gene
expression.
4. Discussion
In this study, we showed that miR-518b was signiﬁcantly
down-regulated in ESCC tissues when compared with adjacentnormal tissue. Furthermore, the expression of miR-518b had a sig-
niﬁcant relationship with lymph node metastasis and survival.
Importantly, we showed that Rap1b expression was negatively
regulated by miR-518b in ESCC cells, suggesting a role for miR-
518b dysregulation in the pathogenesis of ESCC.
Esophageal carcinogenesis is a multi-stage process, involving a
variety of changes in gene expression and physiological structure
change. MiRNAs are a class of small non-coding endogenous RNA




Fig. 3. Effect of miR-518b on cell invasion in vitro. (A) Cell invasion assay. Cells transfected with anti-miR-518b inhibitor (anti-miR-518b), anti-miR-Inhibitors-Negative
Control (Control), pcDNA™6.2-GW/EmGFP-miR-518b (miR-518b) and pcDNA™6.2-GW/EmGFP-miR (Mock) were subjected to transwell invasion assays, as described. After
incubation, cells that invaded through the pores to the under surface of the membrane were ﬁxed, stained and counted. (B) Invading cell numbers are the average count of ﬁve
random microscopic ﬁelds. Each bar represents the mean ± S.D. of the counts from a single representative experiment. ⁄P < 0.05 compared with respective control.
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including cell differentiation, proliferation, and apoptosis. Frequent
dysregulation of miRNAs in malignancy highlights the study of
molecular factors upstream of gene expression to reveal the impor-
tant role of miRNAs in carcinogenesis [10–12].
Reports found that the expression of miRNAs was aberrant in
ESCC, suggesting that miRNAs played an important role in the
progression of ESCC [12–15]. Lots of previous studies have demon-
strated the role of miRNAs, notably miR-21, in the carcinogenesis
of ESCC [16–22]. miR-21 was shown to act as an oncogene in ESCC
through targeting programmed cell death 4(PDCD4) and PTEN [16–
18]. miR-223, miR-205, and miR-375 were down-regulated in ESCC
and had an inhibitory effect on cell invasion [18–20]. A recent
study looking at serum samples taken from 290 ESCC patients
and 140 age- and sex-matched controls showed that a proﬁle of
7 serum miRNAs (miR-10a, miR-22, miR-100, miR-148b, miR-
223, miR-133a, and miR-127-3p) as ESCC biomarkers. More impor-
tantly, this panel of 7 miRNAs clearly distinguished stage I/II ESCC
patients from controls [22].
Our previously study revealed that miR-126 up-regulated
whilst miR-518b and miR-433 down-regulated in ESCC. In this
study, we examined the expression levels of these three miRNAs
in 30 paired specimens and found that miR-518b was signiﬁcantly
down-regulated in ESCC tissues. These results were consistent with
previous studies that miR-518b only expressed in non-tumor tis-
sues compared with hepatocellular carcinoma tissues and miR-
518b was down-regulated in highly invasive pancreatic cancer cell
lines but not in highly metastatic cell lines [23,24]. In addition, the
levels of miR-518b in tumor tissue of patients with lymph node
metastasis were signiﬁcantly lower than in those without lymph
node metastasis. Further, low expression of miR-518b was an inde-
pendent factor indicating a poor prognosis of ESCC patients. Theseresults suggest that down-regulation of miR-518b in tumor cells
may play roles in the development of ESCC and have prognostic
values.
To reveal the exact role of miR-518b in ESCC, we then tested the
effect of miR-518b on proliferation, cell cycle, apoptosis, and inva-
sion by up-and down-regulating the expression level of miR-518b.
The results showed that increased miR-518b inhibited the prolifer-
ation of ESCC cells, while decreased miR-518b promoted prolifera-
tion, suggesting that it could play a role in ESCC tumourgenesis.
miR-518b had no inﬂuence on cell cycle but promoted the apopto-
sis rate, indicating that miR-518b suppressed the ability of ESCC
cells to proliferate by inducing apoptosis in ESCC cells. Since
miR-518b had a relationship with metastasis, we then examined
the implication of miR-518b in ESCC cells invasion, and data
showed that miR-518b had a negative effect on invasion. These
suggest that down-regulation of miR-518b in tumor cells may play
roles in the development of ESCC through enhancing cell prolifer-
ation, inhibiting apoptosis, and promoting cell invasion. However,
these should be conﬁrmed with further in vivo experiments.
Considering the value of miR-518b in metastasis and invasion, it
will be interesting to explore mechanisms mediating miR-518b di-
rectly or indirectly affects cell progression in ESCC. In order to
understand the pathways involved in miR-518b-mediated inhibi-
tion of cell invasion, we investigated potential target genes of
miR-518b. Bioinformatics analysis revealed Rap1b, EGR1, TFAP2A,
HOXC8 and TSN as potential targets. Some of these target genes
have been previously conﬁrmed to involve in tumor progression.
Rap1b is an isoform of Rap1, a small GTPase regulating several ba-
sic cellular functions including adhesion, migration, polarity, dif-
ferentiation, and growth [25]. Studies provided evidence that
Rap1b was required for angiogenesis and had mitogenic properties
[9,26]. We then chose Rap1b for further experiments based on the
Fig. 3 (continued)
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pression of the invasion in ESCC. There were increase expression
of Rap1b in both cells and tissues. Following results showed that
miR-518b could signiﬁcantly down-regulate Rap1b protein expres-
sion, but had no effect on the mRNA expression. So we drew the
conclusion that miR-518b post-transcriptionally regulated expres-
sion of Rap1b. Using a miRNA reporter system, we then showed
that miR-518b speciﬁcally down-regulated endogenous Rap1b
expression at the post-transcriptional level. These results provided
insight into regulation mechanism of miR-518b in ESCC. Rap1b
might be the target via which miR-518b mediates its effects on cellgrowth and invasion. On the other hand, there are opposite obser-
vations in the expression of miR-518b in other cancers. For exam-
ple, miR-518b up-regulated in HCC compared to non-cancerous
tissue and in extranodal marginal zone lymphomas (MALT lym-
phoma) compared to gastritis [27,28]. As known to all, each miRNA
can inﬂuence the expression of several hundred different target
genes containing oncogenes and tumor suppressor genes. In other
words, the action for the anti-tumor or pro-tumor roles of a miRNA
depends on the competition among its target genes in speciﬁc
types of cancer. Thus, we speculate that miR-518b function as a tu-
mor suppressor gene in ESCC was due to the inhibition of its target
Fig. 4. Rap1b was a target of miR-518b. (A–C) The expression of miR-518b and Rap1b in ESCC cells were detected by qRT-PCR or Western blots, respectively, using normal
adjacent tissues (NAT) as control. (D) Immunohistochemical analysis detected the expression of Rap1b protein in tumor tissues compared with NAT (magniﬁcation, 200). (E
and F) Effects of miR-518b on expression of Rap1b in mRNA and protein levels were detected by qRT-PCR or Western blots, respectively. NE represents for normal ESCC cells,
miR-518b represents cells transfected with ‘‘pcDNA™6.2-GW/EmGFP-miR-518b’’, mock represents for cells transfected with ‘‘pcDNA™6.2-GW/EmGFP-miR’’. (G) Schematic
graph of the putative binding sites of miR-518b in the Rap1b 30-UTR (514–520). Mutant of Rap1b indicates the Rap1b 30-UTR with mutation in miR-518b-binding sites. (H–J)
Luciferase assay in Eca109 (H), Ec9706 (I), and TE-1 (J). miR-518b represents cells transfected with ‘‘pcDNA™6.2-GW/EmGFP-miR-518b’’, NE represents for normal ESCC cells,
mock represents for cells transfected with ‘‘pcDNA™6.2-GW/EmGFP-miR’’, pmirGLO represents for pmirGLO luciferase vector, rap1b-m and rap1b-w represents for mutant
and wide type luciferase vector. ⁄P < 0.05 compared with respective control.
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3520 M. Zhang et al. / FEBS Letters 586 (2012) 3508–3521genes, which were mostly oncogenes in ESCC. So it is very impor-
tant to validate targets of miR-518b by further functional assays.
One important limitation of our study is that only 30 patients
were enrolled in the analysis of the clinicopathologic characteris-
tics and the follow up data was only for progress free survival.
We would like to conﬁrm the ﬁndings in a larger patient popula-
tion and analyze the relationship between miR-518b expression
and overall survival.
In conclusion, this study provides new insights into the role of
miR-518b in ESCC. Here we show that miR-518b is down-regulatedin ESCC tissues and correlates with metastasis and survival, and is
able to inhibit cell proliferation and invasion of ESCC cells in vitro.
We used functional assays to conﬁrm that miR-518b down-regu-
lated Rap1b expression in ESCC cells. These results suggest that
miR-518b is a tumor suppressor in ESCC, and might serve as a ther-
apeutic target.
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